Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mycophenolate Mofetil

FDA-approved product (capsule, oral), marketed as Cellcept, Mycophenolate Mofetil, Myhibbin and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Mycophenolate Mofetil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Delayed Graft Function
  • Immune system disease
  • Multiple sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective immunosuppressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mycophenolate Mofetil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mycophenolate Mofetil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • TO Compare the Triple Drug Therapy and Dual Therapy .

    NCT02075242 · start 2014-01

    Registered record
    Registry ID
    NCT02075242
    Conditions
    HEPATITIS
    Interventions
    Mycophenolate Mofetil; Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2016-01
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHEPATITIS
    InterventionMycophenolate Mofetil; Tacrolimus
    PhasePhase 4
    Registry statusUnknown

  • Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children

    NCT01898377 · start 2013-08

    Registered record
    Registry ID
    NCT01898377
    Conditions
    Chronic Graft-versus-host Disease
    Interventions
    Imatinib mesylate, Mycophenolate mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-08
    Completion
    2018-02-14
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Graft-versus-host Disease
    InterventionImatinib mesylate, Mycophenolate mofetil
    PhasePhase 2
    Registry statusTerminated

  • A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

    NCT01878786 · start 2013-06

    Registered record
    Registry ID
    NCT01878786
    Conditions
    Delayed Graft Function
    Interventions
    Everolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2017-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelayed Graft Function
    InterventionEverolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

    NCT01582048 · start 2012-04

    Registered record
    Registry ID
    NCT01582048
    Conditions
    Patients Receiving Mismatched Allogeneic HCT
    Interventions
    immunosuppression
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-04
    Completion
    2016-08-17
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients Receiving Mismatched Allogeneic HCT
    Interventionimmunosuppression
    PhasePhase 2
    Registry statusTerminated

  • A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

    NCT01433978 · start 2012-03-26

    Registered record
    Registry ID
    NCT01433978
    Conditions
    Idiopathic Thrombocytopenic Purpura
    Interventions
    Eltrombopag; Avatrombopag; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-03-26
    Completion
    2013-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Thrombocytopenic Purpura
    InterventionEltrombopag; Avatrombopag; Standard of care
    PhasePhase 3
    Registry statusTerminated

  • Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens

    NCT01428973 · start 2011-09

    Registered record
    Registry ID
    NCT01428973
    Conditions
    Graft-Versus-Host Disease; Hematological Malignancies
    Interventions
    Mycophenolate mofetil; Sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-09
    Completion
    2024-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft-Versus-Host Disease; Hematological Malignancies
    InterventionMycophenolate mofetil; Sirolimus
    PhasePhase 2
    Registry statusUnknown

  • Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

    NCT01154387 · start 2010-07

    Registered record
    Registry ID
    NCT01154387
    Conditions
    End Stage Renal Disease; Renal Transplant
    Interventions
    Anti-Thymocyte Globulin; TOL101; TOL101; Steroids; Tacrolimus; Mycophenolate mofetil (MMF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2010-07
    Completion
    2013-06
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease; Renal Transplant
    InterventionAnti-Thymocyte Globulin; TOL101; TOL101; Steroids +2 more
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

    NCT01015456 · start 2010-01

    Registered record
    Registry ID
    NCT01015456
    Conditions
    Lupus Nephritis
    Interventions
    mycophenolate sodium; cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-01
    Completion
    2013-01
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis
    Interventionmycophenolate sodium; cyclophosphamide
    PhasePhase 3
    Registry statusTerminated

  • Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant

    NCT00970073 · start 2009-08

    Registered record
    Registry ID
    NCT00970073
    Conditions
    Liver Transplantation
    Interventions
    Thymoglobulin 3mg total; Thymoglobulin 4.5mg total; Mycophenolate mofetil; tacrolimus 3-8; tacrolimus 8-12
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-08
    Completion
    2015-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation
    InterventionThymoglobulin 3mg total; Thymoglobulin 4.5mg total; Mycophenolate mofetil; tacrolimus 3-8 +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis

    NCT00843856 · start 2009-03-03

    Registered record
    Registry ID
    NCT00843856
    Conditions
    Glomerulonephritis, Membranous
    Interventions
    tacrolimus; tacrolimus and mycophenolate mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03-03
    Completion
    2018-09-18
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlomerulonephritis, Membranous
    Interventiontacrolimus; tacrolimus and mycophenolate mofetil
    PhasePhase 4
    Registry statusCompleted

  • Polycystic Liver Disease in Kidney Transplant

    NCT00934791 · start 2009-02

    Registered record
    Registry ID
    NCT00934791
    Conditions
    Polycystic Liver Disease
    Interventions
    Tacrolimus; Sirolimus; Mycophenolate Mofetil; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2009-02
    Completion
    2012-12
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Liver Disease
    InterventionTacrolimus; Sirolimus; Mycophenolate Mofetil; Prednisone
    PhaseNot applicable
    Registry statusTerminated

  • Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy Participants

    NCT02981290 · start 2008-07

    Registered record
    Registry ID
    NCT02981290
    Conditions
    Healthy Volunteers
    Interventions
    Renodapt; Mycept; Cellmune; CellCept
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-07
    Completion
    2008-10
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionRenodapt; Mycept; Cellmune; CellCept
    PhasePhase 1
    Registry statusCompleted

  • A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.

    NCT00717314 · start 2008-05

    Registered record
    Registry ID
    NCT00717314
    Conditions
    Liver Transplantation
    Interventions
    Mycophenolate mofetil; CNI (50%); CNI (≥75%)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    2011-07
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation
    InterventionMycophenolate mofetil; CNI (50%); CNI (≥75%)
    PhasePhase 4
    Registry statusCompleted

  • Steroid Withdrawal Immunosuppression After Renal Transplantation

    NCT01550445 · start 2008-05

    Registered record
    Registry ID
    NCT01550445
    Conditions
    Disorder Related to Renal Transplantation
    Interventions
    Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-05
    Completion
    2012-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisorder Related to Renal Transplantation
    InterventionPrednisolone
    PhasePhase 4
    Registry statusUnknown

  • Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

    NCT00634920 · start 2008-03

    Registered record
    Registry ID
    NCT00634920
    Conditions
    Renal Function
    Interventions
    everolimus; cyclosporine A; Enteric Coated Mycophenolate Sodium (EC-MPS); corticosteroids; Basiliximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-03
    Completion
    2013-05
    Enrolment
    204

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Function
    Interventioneverolimus; cyclosporine A; Enteric Coated Mycophenolate Sodium (EC-MPS); corticosteroids +1 more
    PhasePhase 4
    Registry statusCompleted